Market Performance - The Shandong state-owned enterprise reform sector rose by 0.45% compared to the previous trading day, with Xinhua Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3864.18, down 0.15%, while the Shenzhen Component Index closed at 12907.83, up 1.02% [1] Stock Highlights - Xinhua Pharmaceutical (000756) closed at 18.15, up 5.77% with a trading volume of 877,900 shares and a transaction value of 1.595 billion [1] - Inspur Information (000977) closed at 63.56, up 5.74% with a trading volume of 995,400 shares and a transaction value of 6.266 billion [1] - Other notable stocks include Jiri Co. (002083) up 3.50%, Shantui Co. (000680) up 3.02%, and Haizhu Co. (301262) up 3.01% [1] Capital Flow - The Shandong state-owned enterprise reform sector saw a net inflow of 885 million in main funds, while retail investors experienced a net outflow of 449 million [2] - The main funds showed significant inflows into stocks like Inspur Information and Xinhua Pharmaceutical, while retail investors withdrew from several stocks [3] Individual Stock Capital Flow - Inspur Information had a main fund net inflow of 11.37 billion, while retail investors saw a net outflow of 6.40 billion [3] - Xinhua Pharmaceutical experienced a main fund net inflow of 68.2 million, with retail investors withdrawing 46.5 million [3] - Other stocks like Shandong Steel (600022) and Qingdao Food (001219) also showed varied capital flows, indicating differing investor sentiments [3]

Group 1 - Shandong Xinhua Pharmaceutical (000756) shares increased by over 4%, currently trading at 7.49 HKD with a transaction volume of 95.1843 million HKD [1] - The company received approval from the National Medical Products Administration for the registration of Lidocaine and Prilocaine Cream, which is expected to generate approximately 615 million CNY in sales for public medical institutions in China in 2024 [1] - The current season is seeing a rise in demand for flu medications such as Oseltamivir and Marbofloxacin, with sales of Oseltamivir increasing by 237% and Marbofloxacin by 180% over the past week [1] Group 2 - Xinhua Pharmaceutical is a significant global supplier of antipyretic and analgesic medications, with a product portfolio that includes Ibuprofen, Aspirin, and Meloxicam [1]

Core Viewpoint - Shandong Xinhua Pharmaceutical Co., Ltd. has seen its stock price increase by over 4%, currently trading at 7.49 HKD, following the approval of its drug registration certificate for a new compound anesthetic cream by the National Medical Products Administration of China [1] Company Summary - The newly approved drug, Lidocaine and Prilocaine Cream, is intended for local skin anesthesia and is projected to generate sales of approximately 615 million CNY in public medical institutions in China by 2024 [1] - Xinhua Pharmaceutical is a significant global supplier of antipyretic and analgesic medications, with a product portfolio that includes Ibuprofen, Aspirin, and Meloxicam [1] Industry Summary - The current season is marked by a surge in respiratory infectious diseases, leading to increased demand for antiviral medications such as Oseltamivir and Marbofloxacin, with sales growth rates of 237% and 180% respectively over the past week [1]

Core Viewpoint - Xinhua Pharmaceutical has received approval from the National Medical Products Administration for the registration of its drug, Lidocaine and Prilocaine Cream [1] Group 1 - Xinhua Pharmaceutical announced the receipt of the drug registration certificate for Lidocaine and Prilocaine Cream [1]

公告显示，利丙双卡因乳膏是利多卡因和丙胺卡因的复方制剂，用于皮肤局部麻醉。新华制药表示，利 丙双卡因乳膏获批有利于公司开拓新的市场领域，提升公司综合竞争力。 北京商报讯（记者 丁宁）11月25日晚间，新华制药（000756）发布公告称，公司收到国家药品监督管 理局核准签发的利丙双卡因乳膏《药品注册证书》。 ...

山东新华制药股份(00719)发布公告，近日，山东新华制药股份有限公司(以下简称"... 利丙双卡因乳膏是利多卡因和丙胺卡因的复方制剂，用于下列情况的皮肤局部麻醉：1.针穿刺，例如： 置入导管或采血;2.浅层外科手术，例如：粘膜，在浅层外科手术或浸润麻醉之前;腿部溃疡清洁/清创 术。 根据相关统计数据，2024年中国公立医疗机构利丙双卡因乳膏销售额约为人民币6.15亿元。追加内容 本文作者可以追加内容哦 ! 山东新华制药股份(00719)发布公告，近日，山东新华制药股份有限公司(以下简称"新华制药"或"本公 司")收到国家药品监督管理局核准签发的利丙双卡因乳膏(以下简称"本品")《药品注册证书》。 2024年2月，新华制药向国家药品监督管理局药品审评中心(CDE)递交利丙双卡因乳膏境内生产药品上 市许可注册申报资料并获受理，2025年11月获得《药品注册证书》，审评结论为批准注册。 ...

Core Viewpoint - Xinhua Pharmaceutical (000756.SZ) has received approval from the National Medical Products Administration for the registration certificate of Lidocaine and Prilocaine Cream, indicating a significant advancement in its product offerings [1] Group 1: Product Approval - The approved product, Lidocaine and Prilocaine Cream, is a compound formulation used for local anesthesia in various medical procedures [1] - Indications for use include skin local anesthesia for needle punctures, such as catheter insertion or blood sampling, and superficial surgical procedures [1] - The cream is also indicated for cleaning and debridement of leg ulcers, showcasing its versatility in clinical applications [1]

利丙双卡因乳膏是利多卡因和丙胺卡因的复方制剂，用于下列情况的皮肤局部麻醉：1.针穿刺，例如： 置入导管或采血；2.浅层外科手术，例如：生殖器粘膜，在浅层外科手术或浸润麻醉之前；腿部溃疡清 洁/清创术。 格隆汇11月25日丨新华制药(000756.SZ)公布，公司收到国家药品监督管理局核准签发的利丙双卡因乳 膏（简称"本品"）《药品注册证书》。 ...

智通财经APP讯，新华制药(000756.SZ)公告，公司收到国家药品监督管理局核准签发的利丙双卡因乳膏 《药品注册证书》。利丙双卡因乳膏是利多卡因和丙胺卡因的复方制剂，用于下列情况的皮肤局部麻 醉：针穿刺，例如：置入导管或采血;浅层外科手术，例如：生殖器粘膜，在浅层外科手术或浸润麻醉 之前;腿部溃疡清洁/清创术。 ...

近日，山东新华制药股份有限公司（以下简称"新华制药"或"本公司"）收到国家药 品监督管理局核准签发的利丙双卡因乳膏（以下简称"本品"）《药品注册证书》。现将相关 情况公告如下： 一、基本情况 证券代码：000756 证券简称：新华制药 公告编号：2025-67 山东新华制药股份有限公司 关于获得利丙双卡因乳膏药品注册证书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误 导性陈述或重大遗漏。 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品符合药品注 册的有关要求，批准注册，发给药品注册证书。质量标准、说明书、标签及生产工艺照所附 执行。药品生产企业应当符合药品生产质量管理规范要求方可生产销售。 药品名称：利丙双卡因乳膏 剂型：乳膏剂 规格：30g：利多卡因750mg与丙胺卡因750mg 药品分类：处方药 注册分类：化学药品4类 申请人：山东新华制药股份有限公司 申请事项：药品注册（境内生产） 受理号：CYHS2400440 药品批准文号：国药准字H20255987 证书编号：2025S03457 二、其他相关信息 2024年2月，新华制药向国家药品监督管理局 ...